Search results
Results from the WOW.Com Content Network
Here is whether Pfizer stock might be a buy today -- and why. Pfizer's pandemic boom (and bust) shouldn't haunt the stock much longer. Dividend investors will focus on Pfizer's current dividend ...
Pfizer's stock was down 2% in early trading Thursday. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs ...
One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Given how well Pfizer has performed in recent years due to its COVID-19 vaccine and pill (its revenue topped $100 ...
Pfizer posted strong earnings in the third quarter as investors worry about the stock's value. Pfizer raises full-year guidance by $1.5 billion amid activist investor pressure [Video] Skip to main ...
Pfizer's trailing-12-month (TTM) revenue is $59.3 billion, whereas its TTM normalized diluted earnings per share (EPS) is $1.55. Pfizer Just Reassured Investors, but Is the Stock a Buy? Skip to ...
Although Pfizer seems headed toward big things over the coming years, the stock has immediate appeal. Here are three reasons to consider buying Pfizer like there's no tomorrow -- today. 1.
PFE Revenue (TTM) data by YCharts Pfizer's vaccine (Comirnaty) and treatment option (Paxlovid) combined for $56 billion in revenue in 2022. Those two products represented just $2.4 billion of ...
Pfizer CEO Albert Bourla is breathing a little easier after strong third quarter earnings results Tuesday and after the company raised full-year guidance by $1.5 billion, bringing an end to a ...